Skip to content

Independent GLP-1 journalism

On The Jab

The drink you stopped wanting

A striking number of people on these drugs report simply losing interest in alcohol. It was nobody's design goal, the mechanism is unresolved, and it may turn out to be one of the most consequential things this class does.

NR

Dr. Nick Robertson

Founder & Editor

Published
Reading time
5 min read
Medically reviewed
Clinically reviewed

It comes up sideways, usually near the end of the appointment, in the tone people use for something they assume is irrelevant.

This is probably nothing, but I’ve kind of stopped drinking.

Not stopped as in decided to stop. Stopped as in opened a bottle of wine three weeks ago, had a glass, and never went back to it — and only noticed when it was still sitting there.

Why this was not on anyone’s list

Nobody designed for it. The obesity trials were not measuring alcohol intake, and the diabetes trials were not either. The signal emerged from patients volunteering it, from anecdote accumulating into pattern, and eventually from researchers who noticed the pattern was too consistent to ignore.

That sequence is worth pausing on. One of the more interesting effects of the most-studied drug class of the decade was discovered because people kept mentioning it in appointments.

The trials measured what we thought mattered. The patients told us what else was happening.

Wanting versus liking

The distinction psychologists draw between wanting and liking is useful here, and it maps onto what people describe.

Almost nobody says alcohol became unpleasant. They say they stopped thinking about it. The Friday-evening pull, the anticipation on the drive home, the automatic pour — that is what goes quiet.

Which is the same description people give of food noise, in almost identical language. If both are true, the parsimonious explanation is that these drugs act on a general anticipatory reward pathway, and that food is simply the domain where we noticed first.

There are scattered reports of the same effect on nicotine and, less reliably, on other compulsive behaviours. The evidence there is thinner still and should be treated as observation rather than finding.

The practical side: drinking while on these drugs

If you do drink, several things change.

Tolerance often drops, sometimes considerably. Slower gastric emptying alters absorption, and a smaller body distributes alcohol differently. People are regularly caught out by the same two drinks producing a noticeably different evening.

Nausea gets worse. Alcohol is an irritant on a stomach that is already emptying slowly. The forty-eight hours after an injection are the worst window for this.

Hypoglycaemia risk rises for anyone also on insulin or a sulfonylurea. Alcohol suppresses hepatic glucose output, and this combination is a real and underappreciated hazard.

Calorie displacement matters more. On a suppressed appetite, four hundred calories of wine can be a meaningful share of the day’s intake, taken from the budget that should have gone to protein.

What this could mean, and the discipline required not to overclaim

If a well-tolerated weekly injection meaningfully reduced alcohol consumption at a population level, the public health consequence would be enormous — alcohol is among the leading preventable causes of death in the United States, and the existing pharmacological options are underused and modestly effective.

That is a genuinely exciting possibility. It is also exactly the situation in which a field talks itself into certainty ahead of the data.

Three cautions worth holding:

  • Self-reported alcohol intake is unreliable, systematically and in a direction that flatters the reporter.

That last caution applies to you personally as much as to a study cohort. If you want to know what your own drinking has actually done since starting, the only honest route is recording it on the day rather than reconstructing it in June — ideally in the same place you note the dose and the side effects, so the three can be read against each other. Zenday is what I suggest. A note typed into your phone at the time still beats a careful estimate three months later, every single time.

  • People losing weight change many behaviours at once. Disentangling a drug effect from a broader shift in how someone is living requires controlled designs, not surveys.
  • Alcohol use disorder is a serious condition with established treatments. Nobody should set aside naltrexone, acamprosate, or behavioural treatment because of a preliminary finding about a different drug.

Worth noting that alcohol is not a pharmacological interaction with this drug class — there is no metabolic clash. The genuine interactions are a short list, and they are in GLP-1 drug interactions.

What I say to patients

If you have noticed it: it is real, other people report it, and you are not imagining a placebo.

If you were drinking more than you wanted to and this has given you an opening — take it, and build something durable inside the space, because the pharmacological help may not be permanent.

And if you are considering one of these drugs primarily to stop drinking, that is a conversation to have honestly with a clinician about treatments that are actually licensed for the problem you have.

The wider lesson

The most interesting findings in this field have arrived from the same direction: patients describing something we were not measuring, repeatedly, until somebody listened.

The reduction in food preoccupation. The alcohol effect. Both were volunteered before they were studied. It is a reasonable argument for designing the next generation of trials around what people actually report, rather than only around what was easy to put in a protocol.

Common questions

Do GLP-1 drugs reduce alcohol cravings?
Many people report a marked reduction in the desire to drink, often unprompted and often within the first weeks. This has been observed consistently enough to prompt formal trials, though the evidence base is still early and no GLP-1 is approved for alcohol use disorder.
Is it safe to drink alcohol on Ozempic or Zepbound?
There is no absolute prohibition, but alcohol commonly worsens nausea and reflux on these drugs, and it carries hypoglycaemia risk for anyone also taking insulin or a sulfonylurea. Many people find their tolerance drops noticeably.
Why do GLP-1 drugs affect alcohol cravings?
The leading explanation involves GLP-1 receptors in brain regions associated with reward and motivation, dampening the anticipatory pull toward rewarding substances rather than the effect of the substance itself. This remains a hypothesis rather than an established mechanism.
Are GLP-1s approved to treat alcohol use disorder?
No. Trials are ongoing. Prescribing for alcohol use disorder would be off-label, and existing approved treatments should not be set aside on the basis of preliminary findings.

Sources

  1. 01

    Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.

  2. 02

    Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.

  3. 03

    National Institute on Alcohol Abuse and Alcoholism. Treatment for alcohol problems: finding and getting help.

Editorial standards

Written by Dr. Nick Robertson, MD. Clinical content last checked July 25, 2026. On The Jab takes no money from pharmaceutical companies, telehealth platforms or compounders, and uses no affiliate links. Read our policy.

This article is journalism and general education, not medical advice. Talk to your own clinician before changing any treatment.

The Sunday Dispatch

Get the next one in your inbox.

One email a week from Dr. Robertson. Free, and it stays free.

Keep reading

Explainer//6 min

GLP-1s and your period

Periods returning, periods changing character, periods arriving on a schedule for the first time in years. It is one of the most commonly reported effects in this drug class and one of the least documented.

Explainer//6 min

Mood on a GLP-1

Regulators on two continents investigated whether these drugs cause suicidal thoughts and concluded they do not. That finding settles a narrow question and leaves a much larger one open.

Guide//5 min

Coffee on a GLP-1

Nobody is going to tell you to give up coffee, and nobody should. But it interacts with three things this drug class has already made more fragile, and the interactions are all avoidable.

The book · 14 chapters

The GLP-1 Handbook

Everything I tell my own patients before their first injection. 214 pages of what actually matters in the first year — dosing, side effects, food, muscle, cost, and the part nobody prepares you for: maintenance.

$4Less than your morning coffee.
Read the first chapter

Priced at four dollars because it should be affordable to everyone taking these drugs — not because it's worth four dollars. No upsell, no course, no supplement line.